Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 10/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15841376 | 0.99 | ST6GAL1 (0.35) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL4760169 | 0.96 | ST6GAL1 (0.36) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL2216432 | 0.87 | ST6GAL1 (0.36) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL2108247 | 0.87 | ST6GAL1 (0.31) | ST6GAL1 | |
| SCHEMBL15841537 | 0.86 | ST6GAL1 (0.31) | ST6GAL1 | |
| SCHEMBL1319027 | 0.85 | ST6GAL1 (0.37) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL1318619 | 0.84 | NT5E (0.45) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL1317526 | 0.84 | NT5E (0.45) | ST6GAL1NT5ELMNATHRBMTOR | |
| SCHEMBL2107702 | 0.84 | TYMP (0.44) | TYMP | |
| SCHEMBL381896 | 0.83 | ST6GAL1 (0.38) | ST6GAL1NT5ELMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1995253-B1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-1795536-B1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | NIPPON SHINYAKU CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8158775-B2 | Method for detaching protecting group on nucleic acid | NIPPON SHINYAKU CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NIPPON SHINYAKU CO., LTD. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090149645-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2017282-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-1995252-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995253-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NIPPON SHINYAKU CO., LTD. (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1795536-A1 | PHOSPHORAMIDITE COMPOUND AND METHOD FOR PRODUCING OLIGO-RNA | Nippon Shinyaku Co., Ltd. (JP) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312534-A1 | METHOD FOR REMOVAL OF NUCLEIC ACID-PROTECTING GROUP | NSUN2, RNASEH1, RNASE1 | ST6GAL1 516/4885NT5E 936/4885LMNA 268/4885 |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | RNGTT, DUT, ADAR | ST6GAL1 3218/4885NT5E 90/4885LMNA 487/4885 |
| US-20070282097-A1 | Phosphoramidite Compound And Method For Producing Oligo-Rna | NSUN2, NSUN3, XRN2 | ST6GAL1 1832/4885NT5E 1349/4885LMNA 4409/4885 |
| US-20090149645-A1 | METHOD FOR DETACHING PROTECTING GROUP ON NUCLEIC ACID | DNASE1, DNASE1L3, NSUN2 | ST6GAL1 765/4885NT5E 137/4885LMNA 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.